Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial).
Mohammad Hadi MansouriPejman MansouriMasoumeh SadeghiSeyedeh Melika HashemiAlireza KhosraviMohaddeseh BehjatiJavad ShahabiAsieh MansouriReihaneh ZavarAfshin AmirpourHamid SaneiNizal SarrafzadeganPublished in: Clinical cardiology (2023)
Empagliflozin can be safely added as a metabolic modulator agent to existing antianginal medications in individuals with concurrent T2DM and RA to reduce angina symptoms and enhance exercise capacity with minimal side effects.
Keyphrases
- coronary artery disease
- double blind
- coronary artery
- percutaneous coronary intervention
- study protocol
- phase iii
- clinical trial
- placebo controlled
- phase ii
- rheumatoid arthritis
- high intensity
- physical activity
- randomized controlled trial
- acute coronary syndrome
- locally advanced
- open label
- type diabetes
- resistance training
- radiation therapy
- sleep quality
- body composition
- interstitial lung disease
- depressive symptoms
- systemic sclerosis
- insulin resistance